EWTX Form 4: Blaustein receives 17,500 RSUs and 105,000 options
Rhea-AI Filing Summary
Edgewise Therapeutics insider grant: The company reported that Robert Blaustein, Chief Development Officer and director, was granted 17,500 restricted stock units (RSUs) and options to purchase 105,000 shares on 08/12/2025. The RSUs are payable one-for-one upon vesting in four equal annual installments beginning 08/12/2026. The options have an exercise price of $13.39, vest at 1/48th monthly beginning 09/12/2025, and expire 08/12/2035. Following these grants Blaustein beneficially owns 17,500 RSUs and 105,000 option shares directly. The filing was signed by John R. Moore under power of attorney on 08/14/2025.
Positive
- Time-based RSUs and options align executive incentives with long-term company performance
- Clear vesting schedules (RSUs vest in four equal annual installments; options vest monthly) reduce near-term turnover risk
- Full disclosure of exercise price ($13.39), vesting commencement, and expiration dates
Negative
- Potential dilution from 122,500 share-equivalents if RSUs vest and options are exercised
- No outstanding share count provided in this filing, so dilution percentage cannot be assessed from this document alone
Insights
TL;DR: Typical executive equity grants for retention; clear multi-year vesting aligns executive incentives with long-term shareholder value.
The grants consist of time-based RSUs and options with standard 4-year and monthly vesting schedules, respectively. The use of both RSUs and options balances immediate equity alignment with upside performance incentives via options. The exercise price of $13.39 sets a concrete strike for potential future dilution if exercised. Documentation is complete and includes vesting commencement and expiration dates.
TL;DR: Transaction is routine insider compensation; materiality to valuation depends on company share count but appears non-disruptive on its face.
The filing reports insider awards totaling 122,500 share-equivalents. The option term to 2035 is standard for long-dated incentives. Investors should note the exact outstanding share base to quantify dilution; the filing does not provide that figure. All items are directly beneficially owned by the reporting person and properly disclosed under Section 16.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 17,500 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 105,000 | $0.00 | -- |
Footnotes (1)
- Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.
